Lv1
30 积分 2025-08-22 加入
Risk factors of transition from mild cognitive impairment to Alzheimer's disease and death: A cohort study
1天前
待确认
O5‐08‐04: A NEW OPEN‐SOURCE MODELING FRAMEWORK TO ASSESS COST EFFECTIVENESS OF EARLY INTERVENTION IN ALZHEIMER'S DISEASE
5天前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
15天前
已完结
Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review
1个月前
已完结
Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective
2个月前
已完结
Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system
2个月前
已完结
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China
3个月前
已完结
Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective
3个月前
已完结
Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China
3个月前
已完结
Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system
3个月前
已完结
皖公网安备34019202002308
